Latest Hotspot

Carmot Therapeutics starts phase 2 trial for CT-868, a GLP-1/GIP agonist, to treat Type 1 Diabetes

23 November 2023
3 min read

A Phase 2 clinical trial for CT-868, a once-daily dual GLP-1/GIP receptor agonist, in adult subjects who are overweight or obese with T1D, has been initiated by Carmot Therapeutics Inc., a biotechnology company in the clinical phase committed to the creation of transformative treatments for metabolic diseases such as overweightness and diabetes.

👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

Carmot previously showcased outcomes from a different Phase 2 clinical examination of CT-868. This revealed a placebo-controlled decrease in HbA1c by 2.31% from the starting point at the 26th week in participants with type 2 diabetes who were either overweight or obese. 

The 4.0 mg dose was well-accepted, while the most recurring side effects were gastrointestinal and generally minor. The accumulated data, along with precedent experiments for preclinical and clinical action, further enforce the clinical and mechanistic reasoning to consider CT-868 as an additional therapeutic to insulin in treating T1D. 

Beside this Phase 2 clinical testing announced, Carmot is also conducting an ongoing Phase 1b active comparator crossover testing to evaluate the impact of using CT-868 on glucose balance compared to liraglutide in T1D participants. "Advancing to the next level with this Phase 2 clinical examination is a significant progression in CT-868’s clinical course, and we are optimistic about probing CT-868's potential as a supplementary therapy for individuals managing with T1D," stated Manu Chakravarthy, MD, PhD, Chief Scientific & Medical Officer at Carmot. 

"We are truly happy with the advancement in all our three clinical ventures and anticipate multiple data outcomes from our pipeline focused on obesity and diabetes by 2024." CT-868 is among the trio of clinical-phase product contenders in the treatment pipeline at Carmot that aim to tackle obesity and diabetes. 

A crossover clinical trial for 24 T1D participants in Phase 1b will scope out the impact of CT-868, liraglutide, or placebo on glucose balance, measured through a mixed meal tolerance test in a manner independent of weight. 

👇Please click on the picture link below for free registration or login directly if you have freemium accounts, you can browse the latest research progress on drugs, indications, organizations, clinical trials, clinical results, and drug patents related to this target.

图形用户界面

低可信度描述已自动生成

According to the data provided by the Synapse Database, As of November 22, 2023, there are 39 investigational drugs for the GIPR and GLP-1R target, including 24 indications, 29 R&D institutions involved, with related clinical trials reaching 154, and as many as 1328 patents.

CT-868 is a once-daily subcutaneous injectable, dual GLP-1/GIP receptor agonist being developed as an adjunct to insulin for the treatment of people with type 1 diabetes with overweight or obesity. It is currently being studied in a Phase 2 proof-of-concept clinical trial in people with overweight or obesity with T1D and an active comparator Phase 1b mechanism of action crossover clinical trial to assess glucose homeostasis in people with T1D.

图形用户界面, 文本, 应用程序, 网站

描述已自动生成

What are CTLA4 inhibitors and how do you quickly get the latest development progress?
What are CTLA4 inhibitors and how do you quickly get the latest development progress?
23 November 2023
The first immune checkpoint inhibitor for clinical use: CTLA-4 inhibitor. However, it enhances immune function, specifically by boosting the cytotoxicity of immune cells, which often results in more adverse effects.
Read →
Biological Glossary | What is Plasmid?
Bio Sequence
2 min read
Biological Glossary | What is Plasmid?
23 November 2023
A plasmid is a small, circular, double-stranded DNA molecule that is distinct from a cell's chromosomal DNA.
Read →
SNS-101(Sensei Biotherapeutics): A Quick Look at Its R&D Progress and Clinical Results from the 2023 SITC
SNS-101(Sensei Biotherapeutics): A Quick Look at Its R&D Progress and Clinical Results from the 2023 SITC
23 November 2023
The latest clinical result of SNS-101(Sensei Biotherapeutics) in patients with advanced solid tumors was reported at the 2023 SITC Congress, demenstrating its potential efficacy and paving the way for future research.
Read →
Repare Therapeutics launches two clinical trials by 2024: RP-1664 and RP-3467, both oral inhibitors
Latest Hotspot
3 min read
Repare Therapeutics launches two clinical trials by 2024: RP-1664 and RP-3467, both oral inhibitors
23 November 2023
Repare Therapeutics introduces two initiatives set to commence clinical testing by 2024: oral PLK4 inhibitor RP-1664, and oral Polθ inhibitor RP-3467.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.